Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Cited by (864)

Items 401–500 of 864

1. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes
   Kathryn M. Hurren, Marissa Waldman Dunham · 2018 · Expert Opinion on Pharmacotherapy
2. SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?
   Subhankar Chatterjee, Dhrubajyoti Bandyopadhyay, Raktim Kumar Ghosh, Uddalak Majumdar, Ashish Aneja, Carl J. Lavie, PRAKASH C. DEEDWANIA · 2018 · Current Problems in Cardiology
3. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )
   Toru Kitazawa, Hiroaki Seino, Hiroshi Ohashi, Takeshi Inazawa, Masahiro Inoue, Masumi Ai, Midori Fujishiro, Hisamoto Kuroda, Masayo Yamada, Motonobu Anai et al. · 2020 · Diabetes Obesity and Metabolism
4. Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
   Yuxin Huang, Zeju Jiang, Yiping Wei · 2021 · Experimental and Therapeutic Medicine
5. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
   Won Euh, Soo Kyung Lim, Jin‐Wook Kim · 2021 · Frontiers in Endocrinology
6. Anti-diabetic drugs and NASH: from current options to promising perspectives
   Sarra Smati, Clémence M. Canivet, Jérôme Boursier, Bertrand Cariou · 2021 · Expert Opinion on Investigational Drugs
7. Clinical Observation of SGLT2 Inhibitor Therapy for Cardiac Arrhythmia and Related Cardiovascular Disease in Diabetic Patients with Controlled Hypertension
   Shih‐Jie Jhuo, Tsung‐Hsien Lin, Yi‐Hsiung Lin, Wei‐Chung Tsai, I-Hsin Liu, Bin‐Nan Wu, Kun‐Tai Lee, Wen‐Ter Lai · 2022 · Journal of Personalized Medicine
8. New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
   Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Florentin Suman, Ludovica Simonini, Cristina Vassalle · 2024 · International Journal of Molecular Sciences
9. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
   Simona Cernea, Avivit Cahn, Itamar Raz · 2017 · Expert Review of Clinical Pharmacology
10. Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez, Radek Wojcik, Max Schlueter · 2017 · Diabetes Therapy
11. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
    Qiuhe Ji · 2017 · Clinical Therapeutics
12. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials
    Ze Chen, Gerui Li · 2019 · Clinical Drug Investigation
13. Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
    Thomas Marjot, Charlotte Green, Catriona A. Charlton, Thomas Cornfield, Jonathan Hazlehurst, Ahmad Moolla, Sarah J. White, Jane M Francis, Stefan Neubauer, Jeremy Cobbold et al. · 2019 · JGH Open
14. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
    Arbinda Pokharel, Sudhamshu KC, Pukar Thapa, Niyanta Karki, Rupesh Shrestha, Bikash Jaishi, Mukesh Sharma Paudel · 2021 · Cureus
15. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
16. Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients
    Busra Dedemen, Tuba Taslamacıoğlu Duman, Metin Mert Dedemen, Gülali Aktaş · 2024 · Clinical Nutrition ESPEN
17. Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series
    Tania Sundra, Edd Knowles, David I. Rendle, Erin A. Kelty, Guy D. Lester, Gabriele Rossi · 2024 · Domestic Animal Endocrinology
18. SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes
    Qian Wu, Jian Zhang, Fuli Zhang, Dongnan Li · 2025 · Frontiers in Endocrinology
19. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
    Oren Steen, Ronald Goldenberg · 2017 · Canadian Journal of Diabetes
20. Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
    Dan Xu, Owain Chandler, Cleo Wee, Chau Le Bao Ho, Jacquita S. Affandi, Da-Ya David Yang, Xinxue Liao, Wei Chen, Yanbing Li, Christopher Michael Reid et al. · 2021 · Frontiers in Medicine
21. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice
    Tuo Han, Yajie Fan, Jie Gao, Mahreen Fatima, Yali Zhang, Yiming Ding, Liang Bai, Congxia Wang · 2021 · Adipocyte
22. Bioequivalence, Food Effect, and Steady‐State Assessment of Dapagliflozin/Metformin Extended‐release Fixed‐dose Combination Tablets Relative to Single‐component Dapagliflozin and Metformin Extended‐release Tablets in Healthy Subjects
    Ming Chang, Xiaoni Liu, Dapeng Cui, Dan Liang, Frank P. LaCreta, Steven C. Griffen, Susan Lubin, Donette Quamina‐Edghill, David W. Boulton · 2015 · Clinical Therapeutics
23. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
    Maria F. Lorenzi, Uffe Jon Ploug, J Langer, Rasmus Skovgaard, Michael J. Zoratti, Jeroen Paul Jansen · 2016 · Diabetes Therapy
24. A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
    Ashley M. Zurek, Raghunandan Yendapally, Elizabeth M. Urteaga · 2017 · Diabetes Spectrum
25. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
    Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal · 2020 · Advances in experimental medicine and biology
26. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure
    Kayla A. Riggs, Hiba Ali, Heinrich Taegtmeyer, Absalon Gutierrez · 2015 · Metabolic Syndrome and Related Disorders
27. Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS
    Beema T Yoosuf, Muhammed Favas KT, D P Spoorthy, Aasar Saini, Prabha Garg, Sanja Medenica, Pinaki R Dutta, Dipika Bansal · 2025 · Endocrine
28. Cardiovascular-related proteins and the abdominal visceral to subcutaneous adipose tissue ratio
    Lars Lind, Robin Strand, Joel Kullberg, Håkan K. Ahlström · 2020 · Nutrition Metabolism and Cardiovascular Diseases
29. Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions
    Syona S Shetty, ANDREW K. KRUMERMAN · 2022 · Cardiovascular Diabetology
30. Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats
    Liangzhi Zhang, Hengjun Lin, Xudong Yang, Jipeng Shi, Xiusheng Sheng, Lifeng Wang, Ting Li, Helong Quan, Xia Zhai, Wei Li · 2023 · Biomedicine & Pharmacotherapy
31. Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus
    Robert M. Guthrie · 2013 · Postgraduate Medicine
32. Clinical implication of SGLT2 inhibitors in type 2 diabetes
    Go Woon Kim, Sung Hyun Chung · 2014 · Archives of Pharmacal Research
33. Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus
    Stephen Brunton · 2012 · Postgraduate Medicine
34. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    Chaojie Feng, Wu Minxiang, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Chen Zhao, Beiyan Bao · 2019 · International Urology and Nephrology
35. Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease
    Glenn Matthew Chertow, Priya Vart, Niels Jongs, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter R Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto et al. · 2022 · Diabetes Obesity and Metabolism
36. Examining the evidence for weight management in individuals with type 2 diabetes
    Garvey, W. Timothy, Umpierrez, Guillermo E., Dunn, Julia P., Kwan, Anita Y. M., Varnado, Oralee J., Konig, Manige, Levine, Joshua A. · 2022 · Diabetes, Obesity and Metabolism
37. Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial
    Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa · 2020 · Endocrine Journal
38. Dapagliflozin for the treatment of chronic kidney disease
    Yu Kurata, Masaomi Nangaku · 2022 · Expert Review of Endocrinology & Metabolism
39. Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo · 2022 · Advances in Therapy
40. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
    Zengqi Wang, Xueting Hu, Xueying Liu, Yaowen Wang · 2016 · Therapeutics and Clinical Risk Management
41. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial
    Tina Vilsbøll, Ella Ekholm, EVA K. JOHNSSON, Nalina Dronamraju, Serge A Jabbour, Marcus Lind · 2019 · Diabetes Care
42. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
    Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens Juul Holst, Filip Krag Knop, Tina Vilsbøll · 2020 · Diabetes
43. Recent progress in the pharmacotherapy for obesity
    Lu, Jiale, Liu, Pengfei, Cai, Mengyang, Lv, Tongzhe, Zhang, Mengdi, Yin, Kaili, Cheng, Jie, Zhang, Guo · 2025 · European Journal of Pharmacology
44. Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats
    Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Farook, Sofiya Khan, Anuradha Asokan Nair, Nirmal Nachiketh Binu, Mohamed Yehya, Mohammed Moin Khan · 2024 · Biology
45. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus
    Angelo Avogaro, Andrea Giaccari, Paola Fioretto, Stefano Genovese, Francesco Purrello, Francesco Giorgino, Stefano Del Prato · 2017 · Expert Review of Clinical Pharmacology
46. SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
    Elamin Abdelgadir, Fouzia Rashid, Alaaeldin M. Bashier, Razan Ali · 2018 · Journal of Clinical Medicine Research
47. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
    Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Kyung Lim · 2020 · Endocrinology and Metabolism
48. Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
    Angelica Cersosimo, Andrea Drera, Marianna Adamo, Marco Metra, Enrico Vizzardi · 2024 · Kidney and Dialysis
49. Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data
    Sarah R. Bujac, Angelo Del Parigi, Jennifer E. Sugg, Susan Grandy, Tom Liptrot, Martin Karpefors, Chris Chamberlain, Anne-Marie Boothman · 2014 · Diabetes Therapy
50. Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
    Karen S.L. Lam, Chun Chung Chow, K. C. B. Tan, Ronald C.W., Alice P.S. Kong, Peter C.Y. Tong, Man Wo Tsang, Tak Mao Chan, Sydney C.W. Tang, Ka Kui Lee et al. · 2016 · Current Medical Research and Opinion
51. Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
    Takeshi Osonoi, Shinya Nakamoto, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Yusuke Osonoi · 2017 · Journal of Diabetes Investigation
52. Optimizing diabetes treatment in the presence of obesity
    Mary Angelynne Esquivel, Maria Cecilia Lansang · 2017 · Cleveland Clinic Journal of Medicine
53. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action
    Eirini Lioudaki, Emmanuel S. Androulakis, Martin Whyte, Kostas Stylianou, Eugenios Daphnis, Emmanuel S. Ganotakis · 2017 · Cardiovascular Drugs and Therapy
54. Central role of obesity in endothelial cell dysfunction and cardiovascular risk
    José Carlos de Lima Júnior, Alexandre Moura‐Assis, Riobaldo M.R. Cintra, Thiago Quinaglia, Licio Augusto Velloso, Andrei Carvalho Sposito · 2019 · Revista da Associação Médica Brasileira
55. Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
    Meng‐Tzu Weng, Po‐Jen Yang, Pan-Fu Liu, Chin-Hao Chang, Mei–Hsuan Lee, Jin‐Chuan Sheu, Hsiao‐Ching Nien · 2024 · Hepatology International
56. Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
    Justyna Zbrzeźniak, Agata Winiarska, Agnieszka Perkowska‐Ptasińska, Tomasz P. Stompór · 2025 · International Journal of Molecular Sciences
57. New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
    Agni Kakouri, Georgia Kanti, Efthymios Kapantais, Alexandros D. Kokkinos, Leonidas Lanaras, Paul Farajian, Christos Galanakis, Georgios Georgantopoulos, Nikolaos Vlahos, George P. Mastorakos et al. · 2021 · Pharmaceuticals
58. Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets
    Ibrahim AlZaim, Ali Hussein Eid, Khaled S. Abd‐Elrahman, Ahmed Fawzy EL‐Yazbi · 2022 · Biochemical Pharmacology
59. Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?
    Belén Picatoste, Isabel Cerro-Pardo, Luis Miguel Blanco‐Colio, José Luis Martı́n-Ventura · 2023 · Frontiers in Cardiovascular Medicine
60. Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
    Ye Yang, Kyung Wan Min, Seok‐O Park, Kyung‐Soo Kim, Jae Myung Yu, Eun‐Gyoung Hong, Sung‐Rae Cho, Kyu Chang Won, Yong Hyun Kim, Seungjoon Oh et al. · 2023 · Diabetes Obesity and Metabolism
61. The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
    Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh · 2023 · Diabetes Therapy
62. Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Kamlesh K. Bhopale, Mukund P. Srinivasan · 2023 · Livers
63. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
    Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo · 2024 · Cardiovascular Diabetology
64. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
    Shamik J. Parikh, John P.H. Wilding, Serge A Jabbour, Elise Hardy · 2014 · International Journal of Clinical Practice
65. Patient‐reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple‐therapy regimen for 52 weeks
    Susan Grandy, Catarina Sternhufvud, Anna Rydén, Jennifer E. Sugg, Katja Rohwedder · 2015 · Diabetes Obesity and Metabolism
66. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
    В. В. Салухов, Tatiana Yu. Demidova · 2016 · Diabetes Mellitus
67. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
    Eugênio Cersósimo, John M. Miles · 2018 · Current Diabetes Reviews
68. Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
    Yueh‐Ting Lee, Chien‐Ning Hsu, Chung-Ming Fu, Shih‐Wei Wang, Chiang-Chi Huang, Lung‐Chih Li · 2021 · Frontiers in Pharmacology
69. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis
    Steve Kanters, Lars Wilkinson, Hrvoje Vražić, Rohini Sharma, Sarila Hali Kloster Lopes, Evan Popoff, Eric Druyts · 2019 · BMJ Open
70. Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach
    Daniel A. Nadeau · 2013 · Postgraduate Medicine
71. Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials
    Atsunori Kashiwagi, Satoshi Yoshida, Kosei Kawamuki, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Noriko Akiyama, Yoshinori Kondo, Toshio Ogihara · 2016 · Diabetology International
72. Diet intake control is indispensable for the gluconeogenic response to sodium–glucose cotransporter 2 inhibition in male mice
    Emi Hashiuchi, Hitoshi Watanabe, Kumi Kimura, Michihiro Matsumoto, Hiroshi Inoue, Yuka Inaba · 2020 · Journal of Diabetes Investigation
73. Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature
    Qasim Zafar Iqbal, Danil Mishiyev, Zeeshan Zia, Raffaele A Ruggiero, Ghulam Mustafa Aftab · 2020 · Cureus
74. SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
    Lance Alan Sloan · 2024 · Postgraduate Medicine
75. The Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Patients Aged Over 80 Years with Heart Failure
    Kenji Nakano, Kenji Kanenawa, Akihiro Isotani, Takashi Morinaga, Kaori Yamamoto, Norihisa Miyawaki, Euihong Ko, Miho Nakamura, Yuichi Tanaka, Kenichi Ishizu et al. · 2025 · ESC Heart Failure
76. Role of anti-diabetic medications in the management of MASLD
    Scott D. Isaacs, Fiona V Farrelly, Paul Brennan · 2025 · Frontline Gastroenterology
77. Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability
    Tjerk WA de Bruin, Stots B. Reele, Jennifer E. Hamer-Maansson, Shamik J. Parikh, Weifeng Tang · 2015 · Clinical Pharmacology in Drug Development
78. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
    Karun Badwal, Tooba Tariq, Diane Peirce · 2018 · Case Reports in Endocrinology
79. Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
    John C. Clapham · 2019 · Methods in molecular biology
80. Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
    Hiddo J.L. Heerspink · 2019 · Nephrology Dialysis Transplantation
81. Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?
    Kalliopi Pafili, Efstratios S. Maltezos, Νικόλαος Παπάνας · 2017 · Expert Opinion on Pharmacotherapy
82. Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects
    Elizabeth A. Bertran, Helen D Berlie, Aaron Nixon, Linda A. Jaber · 2018 · Clinical Pharmacology in Drug Development
83. Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management
    Mostafa Salama, Bridget K. Biggs, Ana L. Creo, Rose Prissel, Alaa Al Nofal, Seema Kumar · 2023 · Diabetes Metabolic Syndrome and Obesity
84. Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review
    Maria Tziastoudi, Georgios Pissas, Spyridon Golfinopoulos, Georgios Filippidis, Periklis Dousdampanis, Theodoros Eleftheriadis, Ioannis Stefanidis · 2023 · Life
85. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry
    David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, José Ramón González‐Juanatey · 2024 · The American Journal of Medicine
86. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial
    Kanako Kato, Kunihiro Suzuki, Chie Aoki, Masaaki Sagara, Takafumi Niitani, Sho Wakamatsu, Kazunori Yanagi, Yoshimasa Aso · 2017 · Expert Opinion on Pharmacotherapy
87. Durability of response to dapagliflozin: a review of long-term efficacy and safety
    Serge A Jabbour · 2017 · Current Medical Research and Opinion
88. Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
    ADDENDA-BHS2 trial investigators, Riobaldo M.R. Cintra, Alexandre Soares, Ikaro Soares Santos Breder, Daniel Munhoz, Joaquim Barreto, Sheila T. Kimura-Medorima, Pamela Nogueira Cavalcante, Renata Zanchetta, Jéssica da Silva Cunha Breder et al. · 2019 · Diabetology & Metabolic Syndrome
89. Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
    Giulia Ferrannini, Gianluigi Savarese, Lars Rydén · 2021 · Diabetes Research and Clinical Practice
90. Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
    Victor Chien‐Chia Wu, Yanrong Li, Chao‐Yung Wang · 2021 · International Journal of Molecular Sciences
91. Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
    Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang · 2021 · Cardiovascular Drugs and Therapy
92. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
    Marc Evans, Angharad R. Morgan, Stephen Charles Bain, Sarah Davies, Umesh Kumar Dashora, Smeeta Sinha, Samuel Seidu, Dipesh Patel, Hannah Beba, William David Strain · 2022 · Diabetes Therapy
93. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
    Věra Čertíková Chábová, Oskar Zakiyanov · 2022 · International Journal of Molecular Sciences
94. Similarities and Distinctions Between Acetazolamide and Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSE
    Milton Packer, Javed Butler · 2023 · European Journal of Heart Failure
95. Sodium Glucose Cotransporter 2 Inhibitors
    John R. White · 2014 · Medical Clinics of North America
96. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
    Edward C. Chao · 2012 · Core evidence
97. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
    Kalliopi Pafili, Efstratios S. Maltezos, Νικόλαος Παπάνας · 2016 · Expert Opinion on Investigational Drugs
98. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)
    Hitoshi Ishii, Hiroki Nakajima, Nozomu Kamei, Tetsuji Niiya, Toru Hiyoshi, Yuko Hiramori, Shigeyuki Ohtsu, Takashi Noto, Dai Shimono · 2020 · Diabetes Therapy
99. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients
    Eugênio Cersósimo, Carolina Solis‐Herrera, Curtis L. Triplitt · 2014 · Brazilian Journal of Nephrology
100. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
     Wenwen Zheng, Qianxian Qi, Jie Li, Chao‐Jie He, Hongyan Fan · 2025 · Diabetology & Metabolic Syndrome